Breast Cancer Prevention Study: Are Healthy Women Put at Risk by Federally Funded Research? : Hearing Before the Human Resources and Intergovernmental Relations Subcommittee of the Committee on Government Operations, House of Representatives, One Hundred Second Congress, Second Session, October 22, 1992
U.S. Government Printing Office, Jan 1, 1994 - Breast - 272 pages
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
adjuvant BCPT beneﬁts Bernadine Healy blood clots Breast Cancer Action breast cancer prevention breast tumors Cancer Prevention Trial Cancer Research centers Chairman chemoprevention cholesterol clinical trials concern consent document developing breast cancer Director disease dose effects of tamoxifen eligible endometrial cancer estrogen evidence ﬁrst ﬁve Food and Drug GREENWALD Gregory Burke healthy women HEALY high risk hormone human incidence increased risk informed consent informed consent form known risks liver cancer menopausal minority women model informed consent National Cancer Institute Oncology osteoporosis participate patients PAYNE percent placebo postmenopausal women potential premenopausal women prevent breast cancer Public Health questions rats receiving tamoxifen recruitment reduce reported risk factors risk of breast risks and benefits says scientiﬁc side effects signiﬁcant statement subcommittee subjects taking tamoxifen tamoxifen study tamoxifen therapy tamoxifen trial tests tion toxicity treatment uterine cancer woman Women's Health